Erythropoietin prevents vascular inflammation and oxidative stress in subtotal nephrectomized rat aorta beyond haematopoiesis

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 12, 2010, Pages 1139-1146

  Toba, Hiroe ^a   Nakashima, Kohei ^a   Oshima, Yuko ^a   Kojima, Yushi ^a   Tojo, Chisato ^a   Nakano, Arisa ^a   Wang, Jiahong ^a   Kobara, Miyuki ^a   Nakata, Tetsuo ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Aorta; Erythropoietin; Kidney; Nitric oxide synthase

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCOGEN SYNTHASE KINASE 3BETA; OSTEOPONTIN; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; HEMATOPOIESIS; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE; MALE; NEPHRECTOMY; NONHUMAN; OXIDATIVE STRESS; PROTECTION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION; URINE VOLUME; VASCULAR RING; VASCULITIS; VASODILATATION;

ACETYLCHOLINE; ANIMALS; AORTA, THORACIC; BLOOD PRESSURE; CREATININE; ERYTHROPOIETIN, RECOMBINANT; GLYCOGEN SYNTHASE KINASE 3; HEMATOCRIT; HEMATOPOIESIS; HUMANS; HYPERPLASIA; MACROPHAGES; MALE; NADPH OXIDASE; NEPHRECTOMY; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; NITROPRUSSIDE; OSTEOPONTIN; OXIDATIVE STRESS; PROTEINURIA; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, WISTAR; SUPEROXIDES; VASCULITIS; VASODILATION;

EID: 78649737889     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2010.05445.x     Document Type: Article

References (57)

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998; 32 (Suppl.): S112-19.
2. Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J. Hypertens. 1996; 14: 223-8.
3. Gerstein HC, Mann JF, Yi Q et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-6.
4. Henry RM, Kostense PJ, Bos G et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int. 2002; 62: 1402-7.
5. Hillege HL, Janssen WM, Bak AA et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J. Intern. Med. 2001; 249: 519-26.
6. Ritz E, McClellan WM. Overview: Increased cardiovascular risk in patients with minor renal dysfunction: An emerging issue with far-reaching consequences. J. Am. Soc. Nephrol. 2004; 15: 513-16.
7. Sarnak MJ, Levey AS, Schoolwerth AC et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-69.
8. Rostand SG, Brunzell JD, Cannon RO 3rd, Victor RG. Cardiovascular complications in renal failure. J. Am. Soc. Nephrol. 1991; 2: 1053-62.
9. Shulman NB, Ford CE, Hall WD et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989; 13: I80-93.
10. Paschos N, Lykissas MG, Beris AE. The role of erythropoietin as an inhibitor of tissue ischemia. Int. J. Biol. Sci. 2008; 4: 161-8.
11. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J. Biol. Chem. 1977; 252: 5558-64.
12. Jelkmann W. Molecular biology of erythropoietin. Intern. Med. 2004; 43: 649-59.
13. Krantz SB. Erythropoietin. Blood 1991; 77: 419-34.
14. Fisher JW. Erythropoietin: Physiology and pharmacology update. Exp. Biol. Med. 2003; 228: 1-14.
15. Chatterjee PK. Pleiotropic renal actions of erythropoietin. Lancet 2005; 365: 1890-2.
16. Khoshdel A, Carney S, Gillies A et al. Potential roles of erythropoietin in the management of anaemia and other complications diabetes. Diabetes Obes. Metab. 2008; 10: 1-9.
17. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat. Rev. Neurosci. 2005; 6: 484-94.
18. Erbayraktar S, Grasso G, Sfacteria A et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl Acad. Sci. USA 2003; 100: 6741-6.
19. Grasso G, Sfacteria A, Cerami A, Brines M. Erythropoietin as a tissue-protective cytokine in brain injury: What do we know and where do we go? Neuroscientist 2004; 10: 93-8.
20. Leist M, Ghezzi P, Grasso G et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 305: 239-42.
21. Sakanaka M, Wen TC, Matsuda S et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc. Natl Acad. Sci. USA 1998; 95: 4635-40.
22. Ehrenreich H, Hasselblatt M, Dembowski C et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 2002; 8: 495-505.
23. Heeschen C, Aicher A, Lehmann R et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003; 102: 1340-6.
24. Lipsic E, Schoemaker RG, Van Der Meer P, Voors AA, Van Veldhuisen DJ, Van Gilst WH. Protective effects of erythropoietin in cardiac ischemia: From bench to bedside. J. Am. Coll. Cardiol. 2006; 48: 2161-7.
25. Bahlmann FH. Use of erythropoietin for cardiovascular protection. Cardiovasc. Drugs Ther. 2008; 22: 253-5.
26. Toba H, Sawai N, Morishita M et al. Chronic treatment with recombinant human erythropoietin exerts renoprotective effects beyond hematopoiesis in streptozotocin-induced diabetic rat. Eur. J. Pharmacol. 2009; 612: 106-14.
27. Hasdan G, Benchetrit S, Rashid G, Green J, Bernheim J, Rathaus M. Endothelial dysfunction and hypertension in 5/6 nephrectomized rats are mediated by vascular superoxide. Kidney Int. 2002; 61: 586-90.
28. Kohler R, Eichler I, Schonfelder H et al. Impaired EDHF-mediated vasodilation and function of endothelial Ca-activated K channels in uremic rats. Kidney Int. 2005; 67: 2280-7.
29. Morris ST, McMurray JJ, Spiers A, Jardine AG. Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int. 2001; 60: 1077-82.
30. Tatematsu S, Wakino S, Kanda T et al. Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease. J. Am. Soc. Nephrol. 2007; 18: 741-9.
31. Morris ST, McMurray JJ, Rodger RS, Jardine AG. Impaired endothelium-dependent vasodilatation in uraemia. Nephrol. Dial. Transplant. 2000; 15: 1194-200.
32. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. Abnormalities of endothelial function in patients with predialysis renal failure. Heart 2000; 83: 205-9.
33. Van Guldener C, Lambert J, Janssen MJ, Donker AJ, Stehouwer CD. Endothelium-dependent vasodilatation and distensibility of large arteries in chronic haemodialysis patients. Nephrol. Dial. Transplant. 1997; 12: 14-18.
34. Russo G, Leopold JA, Loscalzo J. Vasoactive substances: Nitric oxide and endothelial dysfunction in atherosclerosis. Vascul. Pharmacol. 2002; 38: 259-69.
35. Bellizzi V, Sabbatini M, Fuiano G et al. The impact of early normalization of haematocrit by erythropoietin on renal damage in the remnant kidney model. Nephrol. Dial. Transplant. 1998; 13: 2210-15.
36. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170: 191-203.
37. Ross R. Atherosclerosis: An inflammatory disease. N. Engl. J. Med. 1999; 340: 115-26.
38. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J. Clin. Invest. 1993; 92: 1686-96.
39. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ. Res. 1994; 74: 214-24.
40. Senger DR, Ledbetter SR, Claffey KP, Papadopoulos-Sergiou A, Peruzzi CA, Detmar M. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am. J. Pathol. 1996; 149: 293-305.
41. Ikeda T, Shirasawa T, Esaki Y, Yoshiki S, Hirokawa K. Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J. Clin. Invest. 1993; 92: 2814-20.
42. Yazihan N, Karakurt O, Ataoglu H. Erythropoietin reduces lipopolysaccharide-induced cell damage and midkine secretion in U937 human histiocytic lymphoma cells. Adv. Ther. 2008; 25: 502-14.
43. Harrison DG, Cai H, Landmesser U, Griendling KK. Interactions of angiotensin II with NAD(P)H oxidase, oxidant stress and cardiovascular disease. J. Renin Angiotensin Aldosterone Syst. 2003; 4: 51-61.
44. Sorescu D, Weiss D, Lassegue B et al. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 2002; 105: 1429-35.
45. Cetin H, Olgar S, Oktem F et al. Novel evidence suggesting an anti-oxidant property for erythropoietin on vancomycin-induced nephrotoxicity in a rat model. Clin. Exp. Pharmacol. Physiol. 2007; 34: 1181-5.
46. Katavetin P, Inagi R, Miyata T et al. Erythropoietin induces heme oxygenase-1 expression and attenuates oxidative stress. Biochem. Biophys. Res. Commun. 2007; 359: 928-34.
47. Patel NS, Sharples EJ, Cuzzocrea S et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. Kidney Int. 2004; 66: 983-9.
48. Cai Z, Semenza GL. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia/reperfusion injury. Circulation 2004; 109: 2050-3.
49. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-7.
50. Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002; 106: 2973-9.
51. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell Biol. 1998; 10: 262-7.
52. Alessi DR, Cohen P. Mechanism of activation and function of protein kinase B. Curr. Opin. Genet. Dev. 1998; 8: 55-62.
53. Moncada S, Palmer RM, Higgs EA. Nitric oxide. Physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991; 43: 109-42.
54. Urao N, Okigaki M, Yamada H et al. Erythropoietin-mobilized endothelial progenitors enhance reendothelialization via Akt-endothelial nitric oxide synthase activation and prevent neointimal hyperplasia. Circ. Res. 2006; 98: 1405-13.
55. Santhanam AV, Smith LA, Nath KA, Katusic ZS. In vivo stimulatory effect of erythropoietin on endothelial nitric oxide synthase in cerebral arteries. Am. J. Physiol. Heart Circ. Physiol. 2006; 291: H781-6.
56. Burger D, Lei M, Geoghegan-Morphet N, Lu X, Xenocostas A, Feng Q. Erythropoietin protects cardiomyocytes from apoptosis via up-regulation of endothelial nitric oxide synthase. Cardiovasc. Res. 2006; 72: 51-9.
57. D'Uscio LV, Smith LA, Santhanam AV, Richardson D, Nath KA, Katusic ZS. Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin. Hypertension 2007; 49: 1142-8.